Skip to content

High Water Intake to Slow Progression of Polycystic Kidney Disease

The Effect of Water Loading on Urinary Biomarkers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00784030
Enrollment
23
Registered
2008-11-03
Start date
2008-11-30
Completion date
2009-05-31
Last updated
2016-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney, Polycystic, Autosomal Dominant

Keywords

Autosomal Dominant Polycystic Kidney Disease, Polycystic Kidney Disease, Water Loading, Biomarkers

Brief summary

Polycystic kidney disease (PKD) is a genetic disease that occurs in 1 in 500 individuals and leads to kidney failure in half of all affected. Currently, no treatments exist for PKD. PKD-affected kidney cells divide and multiply inappropriately, and form fluid-filled sacs called cysts. Kidney cysts continue to grow throughout life, destroying normal kidney tissue, leading to kidney failure. Based on evidence from basic science research it is believed that drinking high amounts of water can slow the abnormal cysts growth. This study aims to look at changes in urine composition with high water intake in PKD-affected persons compared to healthy individuals.

Interventions

OTHERWater

Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of Autosomal Dominant Polycystic Kidney Disease by history, ultrasound, CT or MRI * Healthy subjects without a diagnosis of Polycystic Kidney Disease by history, ultrasound, CT or MRI * Ages between 18 and 65 * Healthy subjects (without Polycystic Kidney Disease) must have an estimated glomerular filtration rate (eGFR by the MDRD equation) \> 60 ml/min/1.73 m2 with no history of kidney disease

Exclusion criteria

* Women who are pregnant or nursing * Active dependency on drugs or alcohol * Diagnosis of syndrome of inappropriate antidiuresis * Currently taking a vasopressin agonist or antagonist * Blood sodium level less than \< 135 mEq/L * For healthy participants, estimated glomerular filtration rate (level of kidney function) less than \< 60 ml/min/1.73 m2

Design outcomes

Primary

MeasureTime frameDescription
Change in Urine cAMP Concentration and Urine Osmolality (UOsm)pre- and post-water loading (2 hours)Urine cAMP (UcAMP) concentration and urine osmolality UOsm) were measured pre- and post-water loading: with 2.5L over 2 hours

Countries

United States

Participant flow

Participants by arm

ArmCount
Polycystic Kidney Disease (PKD) Patients13
Healthy Patients10
Total23

Baseline characteristics

CharacteristicPolycystic Kidney Disease (PKD) PatientsHealthy PatientsTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
13 Participants10 Participants23 Participants
Sex: Female, Male
Female
8 Participants7 Participants15 Participants
Sex: Female, Male
Male
5 Participants3 Participants8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 130 / 10
serious
Total, serious adverse events
0 / 130 / 10

Outcome results

Primary

Change in Urine cAMP Concentration and Urine Osmolality (UOsm)

Urine cAMP (UcAMP) concentration and urine osmolality UOsm) were measured pre- and post-water loading: with 2.5L over 2 hours

Time frame: pre- and post-water loading (2 hours)

Population: Number of participants was deemed to be adequate for the purposes of this pilot study

ArmMeasureValue (MEAN)Dispersion
Polycystic Kidney Disease PatientsChange in Urine cAMP Concentration and Urine Osmolality (UOsm)-2.6 fold change in cAMP/UOsm (umol/UOsm)Standard Error 0.2
Healthy ControlsChange in Urine cAMP Concentration and Urine Osmolality (UOsm)-2.0 fold change in cAMP/UOsm (umol/UOsm)Standard Error 0.1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026